Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2003-03

AUTHORS

D. J. Kwekkeboom, W. H. Bakker, B. L. Kam, J. J. M. Teunissen, P. P. M. Kooij, W. W. de Herder, R. A. Feelders, C. H. J. van Eijck, M. de Jong, A. Srinivasan, J. L. Erion, E. P. Krenning

ABSTRACT

Medical treatment and chemotherapy are seldom successful in achieving objective tumour reduction in patients with metastatic neuroendocrine tumours. Treatment with the radiolabelled somatostatin analogue [(90)Y-DOTA(0),Tyr(3)]octreotide may result in partial remissions in 10-25% of patients. The newer analogue [DOTA(0),Tyr(3)]octreotate (octreotate) has a ninefold higher affinity for the somatostatin receptor subtype 2 as compared with [DOTA(0),Tyr(3)]octreotide. Also, labelled with the beta- and gamma-emitting radionuclide (177)Lu, it has proved very successful in achieving tumour regression in animal models. The effects of (177)Lu-octreotate therapy were studied in 35 patients with neuroendocrine gastro-entero-pancreatic (GEP) tumours who underwent follow-up for 3-6 months after receiving their final dose. Patients were treated with doses of 100, 150 or 200 mCi (177)Lu-octreotate, to a final cumulative dose of 600-800 mCi, with treatment intervals of 6-9 weeks. Nausea and vomiting within the first 24 h after administration were present in 30% and 14% of the administrations, respectively. WHO toxicity grade 3 anaemia, leucocytopenia and thrombocytopenia occurred after 0%, 1% and 1% of the administrations, respectively. Serum creatinine and creatinine clearance did not change significantly. The effects of the therapy on tumour size were evaluable in 34 patients. Three months after the final administration, complete remission was found in one patient (3%), partial remission in 12 (35%), stable disease in 14 (41%) and progressive disease in seven (21%), including three patients who died during the treatment period. Tumour response was positively correlated with a high uptake on the octreoscan, limited hepatic tumour mass and a high Karnofsky Performance Score. Because of the limited efficacy of alternative therapies, many physicians currently adopt an expectant attitude when dealing with patients with metastatic GEP tumours. However, in view of the high success rate of therapy with (177)Lu-octreotate and the absence of serious side-effects, we advocate its use in patients with GEP tumours without waiting for tumour progression. More... »

PAGES

417-422

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00259-002-1050-8

DOI

http://dx.doi.org/10.1007/s00259-002-1050-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1045597456

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/12634971


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Abdominal Pain", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Alopecia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gastrointestinal Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nausea", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neuroendocrine Tumors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Octreotide", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organometallic Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vomiting", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kwekkeboom", 
        "givenName": "D. J.", 
        "id": "sg:person.01173646252.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173646252.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bakker", 
        "givenName": "W. H.", 
        "id": "sg:person.01033346556.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033346556.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kam", 
        "givenName": "B. L.", 
        "id": "sg:person.01024070503.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024070503.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Teunissen", 
        "givenName": "J. J. M.", 
        "id": "sg:person.01045127457.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045127457.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kooij", 
        "givenName": "P. P. M.", 
        "id": "sg:person.01166065522.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166065522.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Herder", 
        "givenName": "W. W.", 
        "id": "sg:person.01051362103.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051362103.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feelders", 
        "givenName": "R. A.", 
        "id": "sg:person.015464766204.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015464766204.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "van Eijck", 
        "givenName": "C. H. J.", 
        "id": "sg:person.015263522637.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015263522637.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "de Jong", 
        "givenName": "M.", 
        "id": "sg:person.010303004202.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010303004202.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mallinckrodt (United States)", 
          "id": "https://www.grid.ac/institutes/grid.421513.0", 
          "name": [
            "Mallinckrodt Medical, St. Louis, Missouri USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Srinivasan", 
        "givenName": "A.", 
        "id": "sg:person.0651054044.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651054044.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mallinckrodt (United States)", 
          "id": "https://www.grid.ac/institutes/grid.421513.0", 
          "name": [
            "Mallinckrodt Medical, St. Louis, Missouri USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Erion", 
        "givenName": "J. L.", 
        "id": "sg:person.01035534755.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035534755.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Erasmus University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.5645.2", 
          "name": [
            "Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands", 
            "Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Krenning", 
        "givenName": "E. P.", 
        "id": "sg:person.01255444752.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255444752.54"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1111/j.1572-0241.2000.03210.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003148742", 
          "https://doi.org/10.1111/j.1572-0241.2000.03210.x"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0215(20010601)92:5<628::aid-ijc1244>3.0.co;2-l", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021202182"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/snuc/2002.31025", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031251521"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590050034", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036382831", 
          "https://doi.org/10.1007/s002590050034"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/02841869309083916", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036734663"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/snuc.2002.31027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040001058"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1159/000201081", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043869401"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590100574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045446163", 
          "https://doi.org/10.1007/s002590100574"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002590100490", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046278069", 
          "https://doi.org/10.1007/s002590100490"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1023/a:1011160913619", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1056305006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/85.5.365", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059818446"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074964197", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083239197", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2003-03", 
    "datePublishedReg": "2003-03-01", 
    "description": "Medical treatment and chemotherapy are seldom successful in achieving objective tumour reduction in patients with metastatic neuroendocrine tumours. Treatment with the radiolabelled somatostatin analogue [(90)Y-DOTA(0),Tyr(3)]octreotide may result in partial remissions in 10-25% of patients. The newer analogue [DOTA(0),Tyr(3)]octreotate (octreotate) has a ninefold higher affinity for the somatostatin receptor subtype 2 as compared with [DOTA(0),Tyr(3)]octreotide. Also, labelled with the beta- and gamma-emitting radionuclide (177)Lu, it has proved very successful in achieving tumour regression in animal models. The effects of (177)Lu-octreotate therapy were studied in 35 patients with neuroendocrine gastro-entero-pancreatic (GEP) tumours who underwent follow-up for 3-6 months after receiving their final dose. Patients were treated with doses of 100, 150 or 200 mCi (177)Lu-octreotate, to a final cumulative dose of 600-800 mCi, with treatment intervals of 6-9 weeks. Nausea and vomiting within the first 24 h after administration were present in 30% and 14% of the administrations, respectively. WHO toxicity grade 3 anaemia, leucocytopenia and thrombocytopenia occurred after 0%, 1% and 1% of the administrations, respectively. Serum creatinine and creatinine clearance did not change significantly. The effects of the therapy on tumour size were evaluable in 34 patients. Three months after the final administration, complete remission was found in one patient (3%), partial remission in 12 (35%), stable disease in 14 (41%) and progressive disease in seven (21%), including three patients who died during the treatment period. Tumour response was positively correlated with a high uptake on the octreoscan, limited hepatic tumour mass and a high Karnofsky Performance Score. Because of the limited efficacy of alternative therapies, many physicians currently adopt an expectant attitude when dealing with patients with metastatic GEP tumours. However, in view of the high success rate of therapy with (177)Lu-octreotate and the absence of serious side-effects, we advocate its use in patients with GEP tumours without waiting for tumour progression.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00259-002-1050-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1297401", 
        "issn": [
          "1619-7070", 
          "1619-7089"
        ], 
        "name": "European Journal of Nuclear Medicine and Molecular Imaging", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "30"
      }
    ], 
    "name": "Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate", 
    "pagination": "417-422", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "d933672dbdcd910ae97f1d277f0e98783715eec99d7afc8b0e7e0643ce7d15d6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "12634971"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101140988"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00259-002-1050-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1045597456"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00259-002-1050-8", 
      "https://app.dimensions.ai/details/publication/pub.1045597456"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000350_0000000350/records_77574_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1998890/"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00259-002-1050-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00259-002-1050-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00259-002-1050-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00259-002-1050-8'


 

This table displays all metadata directly associated to this object as RDF triples.

260 TRIPLES      21 PREDICATES      59 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00259-002-1050-8 schema:about N0c8947781eb843d69fb5e53750290b4a
2 N0f603d232cdf438e995b7851c852a6c5
3 N0fca5f17d27d42dc81503a04651fb94f
4 N127793be20c548b9b599628bb4e5c781
5 N47c67e073db04ae2879baba464cd8ed7
6 N483f6b0fbd4642afa19fed5c8ac1a5de
7 N507ca96c1f56453fbe220eae78953954
8 N530dd4b27ceb41848fde5ddb0a8754a4
9 N77310e3d719243088a684c80c4dd50b1
10 N7b6b53c69a9e4944a1ab5cc8699c3fe1
11 Na4700bed0b354e37b05d142e76965491
12 Na87e577df5fb45659e26db105e1c33e1
13 Nbbd59e4d1b3b44bd9fb5c2895191decf
14 Nc8c647b029b2484192b3563c46ab921c
15 Nd465f41c8a054f46b9ee5fe403c9e671
16 Nfb408850e3614fcea764f4c56e006397
17 Nff21d7266a5b411db871e9b69921f5e7
18 anzsrc-for:11
19 anzsrc-for:1112
20 schema:author Neeef643deaec4c08a0a0e4c74d760638
21 schema:citation sg:pub.10.1007/s002590050034
22 sg:pub.10.1007/s002590100490
23 sg:pub.10.1007/s002590100574
24 sg:pub.10.1111/j.1572-0241.2000.03210.x
25 https://app.dimensions.ai/details/publication/pub.1074964197
26 https://app.dimensions.ai/details/publication/pub.1083239197
27 https://doi.org/10.1002/1097-0215(20010601)92:5<628::aid-ijc1244>3.0.co;2-l
28 https://doi.org/10.1023/a:1011160913619
29 https://doi.org/10.1053/snuc.2002.31027
30 https://doi.org/10.1053/snuc/2002.31025
31 https://doi.org/10.1093/jnci/85.5.365
32 https://doi.org/10.1159/000201081
33 https://doi.org/10.3109/02841869309083916
34 schema:datePublished 2003-03
35 schema:datePublishedReg 2003-03-01
36 schema:description Medical treatment and chemotherapy are seldom successful in achieving objective tumour reduction in patients with metastatic neuroendocrine tumours. Treatment with the radiolabelled somatostatin analogue [(90)Y-DOTA(0),Tyr(3)]octreotide may result in partial remissions in 10-25% of patients. The newer analogue [DOTA(0),Tyr(3)]octreotate (octreotate) has a ninefold higher affinity for the somatostatin receptor subtype 2 as compared with [DOTA(0),Tyr(3)]octreotide. Also, labelled with the beta- and gamma-emitting radionuclide (177)Lu, it has proved very successful in achieving tumour regression in animal models. The effects of (177)Lu-octreotate therapy were studied in 35 patients with neuroendocrine gastro-entero-pancreatic (GEP) tumours who underwent follow-up for 3-6 months after receiving their final dose. Patients were treated with doses of 100, 150 or 200 mCi (177)Lu-octreotate, to a final cumulative dose of 600-800 mCi, with treatment intervals of 6-9 weeks. Nausea and vomiting within the first 24 h after administration were present in 30% and 14% of the administrations, respectively. WHO toxicity grade 3 anaemia, leucocytopenia and thrombocytopenia occurred after 0%, 1% and 1% of the administrations, respectively. Serum creatinine and creatinine clearance did not change significantly. The effects of the therapy on tumour size were evaluable in 34 patients. Three months after the final administration, complete remission was found in one patient (3%), partial remission in 12 (35%), stable disease in 14 (41%) and progressive disease in seven (21%), including three patients who died during the treatment period. Tumour response was positively correlated with a high uptake on the octreoscan, limited hepatic tumour mass and a high Karnofsky Performance Score. Because of the limited efficacy of alternative therapies, many physicians currently adopt an expectant attitude when dealing with patients with metastatic GEP tumours. However, in view of the high success rate of therapy with (177)Lu-octreotate and the absence of serious side-effects, we advocate its use in patients with GEP tumours without waiting for tumour progression.
37 schema:genre research_article
38 schema:inLanguage en
39 schema:isAccessibleForFree true
40 schema:isPartOf N459b0b1e15014fd4a98061dbd8ed7f4e
41 N5fb87f734bfb4610a3ab7bc7f940d074
42 sg:journal.1297401
43 schema:name Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate
44 schema:pagination 417-422
45 schema:productId N41ff0c5ee89646afa39ec23f6e1fd464
46 N4affb958a3904a83818226a3d47d12fb
47 N6de971fe863f47e18af9af346e4bcdbb
48 Na39d2e4def47488da8d181ba7df533db
49 Ncc91f9a138904726859127c1f28b3586
50 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045597456
51 https://doi.org/10.1007/s00259-002-1050-8
52 schema:sdDatePublished 2019-04-11T10:50
53 schema:sdLicense https://scigraph.springernature.com/explorer/license/
54 schema:sdPublisher N429f583072174faa8f78603bfa4fc0e3
55 schema:url http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1998890/
56 sgo:license sg:explorer/license/
57 sgo:sdDataset articles
58 rdf:type schema:ScholarlyArticle
59 N0c8947781eb843d69fb5e53750290b4a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
60 schema:name Male
61 rdf:type schema:DefinedTerm
62 N0f603d232cdf438e995b7851c852a6c5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
63 schema:name Middle Aged
64 rdf:type schema:DefinedTerm
65 N0fca5f17d27d42dc81503a04651fb94f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Aged
67 rdf:type schema:DefinedTerm
68 N127793be20c548b9b599628bb4e5c781 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
69 schema:name Abdominal Pain
70 rdf:type schema:DefinedTerm
71 N3be514e41f7e4a5faefc0d7e76196886 rdf:first sg:person.01024070503.48
72 rdf:rest Nc2d4dcd191b74047b1c855968fd4b98b
73 N3ef1fd69a11d4c41be9787c951fd7004 rdf:first sg:person.015263522637.41
74 rdf:rest Nf905b328d6424756b62a06429485620e
75 N41ff0c5ee89646afa39ec23f6e1fd464 schema:name dimensions_id
76 schema:value pub.1045597456
77 rdf:type schema:PropertyValue
78 N429f583072174faa8f78603bfa4fc0e3 schema:name Springer Nature - SN SciGraph project
79 rdf:type schema:Organization
80 N452bb6738066483fb9450b4b35fdda30 rdf:first sg:person.01035534755.26
81 rdf:rest Nd99be5d1923a4504a6224c52b7fa891d
82 N459b0b1e15014fd4a98061dbd8ed7f4e schema:volumeNumber 30
83 rdf:type schema:PublicationVolume
84 N47c67e073db04ae2879baba464cd8ed7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Vomiting
86 rdf:type schema:DefinedTerm
87 N483f6b0fbd4642afa19fed5c8ac1a5de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
88 schema:name Organometallic Compounds
89 rdf:type schema:DefinedTerm
90 N4affb958a3904a83818226a3d47d12fb schema:name readcube_id
91 schema:value d933672dbdcd910ae97f1d277f0e98783715eec99d7afc8b0e7e0643ce7d15d6
92 rdf:type schema:PropertyValue
93 N507ca96c1f56453fbe220eae78953954 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Adult
95 rdf:type schema:DefinedTerm
96 N530dd4b27ceb41848fde5ddb0a8754a4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
97 schema:name Radiopharmaceuticals
98 rdf:type schema:DefinedTerm
99 N5fb87f734bfb4610a3ab7bc7f940d074 schema:issueNumber 3
100 rdf:type schema:PublicationIssue
101 N6de971fe863f47e18af9af346e4bcdbb schema:name nlm_unique_id
102 schema:value 101140988
103 rdf:type schema:PropertyValue
104 N77310e3d719243088a684c80c4dd50b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Female
106 rdf:type schema:DefinedTerm
107 N7b6b53c69a9e4944a1ab5cc8699c3fe1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Octreotide
109 rdf:type schema:DefinedTerm
110 N97e4189991204611a3dfb6944d9e91fa rdf:first sg:person.01051362103.02
111 rdf:rest Na65c6adfed434e399d1a8cb9274926a5
112 Na39d2e4def47488da8d181ba7df533db schema:name doi
113 schema:value 10.1007/s00259-002-1050-8
114 rdf:type schema:PropertyValue
115 Na4700bed0b354e37b05d142e76965491 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Alopecia
117 rdf:type schema:DefinedTerm
118 Na65c6adfed434e399d1a8cb9274926a5 rdf:first sg:person.015464766204.49
119 rdf:rest N3ef1fd69a11d4c41be9787c951fd7004
120 Na71c7e225c324b26b13970c3361e9569 rdf:first sg:person.01166065522.26
121 rdf:rest N97e4189991204611a3dfb6944d9e91fa
122 Na87e577df5fb45659e26db105e1c33e1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Neuroendocrine Tumors
124 rdf:type schema:DefinedTerm
125 Nbbd59e4d1b3b44bd9fb5c2895191decf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
126 schema:name Pancreatic Neoplasms
127 rdf:type schema:DefinedTerm
128 Nc2d4dcd191b74047b1c855968fd4b98b rdf:first sg:person.01045127457.55
129 rdf:rest Na71c7e225c324b26b13970c3361e9569
130 Nc8c647b029b2484192b3563c46ab921c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Gastrointestinal Neoplasms
132 rdf:type schema:DefinedTerm
133 Ncbc7d70a5ec24f6ca3249b260130a062 rdf:first sg:person.01033346556.30
134 rdf:rest N3be514e41f7e4a5faefc0d7e76196886
135 Ncc91f9a138904726859127c1f28b3586 schema:name pubmed_id
136 schema:value 12634971
137 rdf:type schema:PropertyValue
138 Nd465f41c8a054f46b9ee5fe403c9e671 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Humans
140 rdf:type schema:DefinedTerm
141 Nd99be5d1923a4504a6224c52b7fa891d rdf:first sg:person.01255444752.54
142 rdf:rest rdf:nil
143 Nee0b68fd823247019cf930aee8f8efb7 rdf:first sg:person.0651054044.43
144 rdf:rest N452bb6738066483fb9450b4b35fdda30
145 Neeef643deaec4c08a0a0e4c74d760638 rdf:first sg:person.01173646252.65
146 rdf:rest Ncbc7d70a5ec24f6ca3249b260130a062
147 Nf905b328d6424756b62a06429485620e rdf:first sg:person.010303004202.42
148 rdf:rest Nee0b68fd823247019cf930aee8f8efb7
149 Nfb408850e3614fcea764f4c56e006397 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Treatment Outcome
151 rdf:type schema:DefinedTerm
152 Nff21d7266a5b411db871e9b69921f5e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Nausea
154 rdf:type schema:DefinedTerm
155 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
156 schema:name Medical and Health Sciences
157 rdf:type schema:DefinedTerm
158 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
159 schema:name Oncology and Carcinogenesis
160 rdf:type schema:DefinedTerm
161 sg:journal.1297401 schema:issn 1619-7070
162 1619-7089
163 schema:name European Journal of Nuclear Medicine and Molecular Imaging
164 rdf:type schema:Periodical
165 sg:person.01024070503.48 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
166 schema:familyName Kam
167 schema:givenName B. L.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024070503.48
169 rdf:type schema:Person
170 sg:person.010303004202.42 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
171 schema:familyName de Jong
172 schema:givenName M.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010303004202.42
174 rdf:type schema:Person
175 sg:person.01033346556.30 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
176 schema:familyName Bakker
177 schema:givenName W. H.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01033346556.30
179 rdf:type schema:Person
180 sg:person.01035534755.26 schema:affiliation https://www.grid.ac/institutes/grid.421513.0
181 schema:familyName Erion
182 schema:givenName J. L.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035534755.26
184 rdf:type schema:Person
185 sg:person.01045127457.55 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
186 schema:familyName Teunissen
187 schema:givenName J. J. M.
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01045127457.55
189 rdf:type schema:Person
190 sg:person.01051362103.02 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
191 schema:familyName de Herder
192 schema:givenName W. W.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01051362103.02
194 rdf:type schema:Person
195 sg:person.01166065522.26 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
196 schema:familyName Kooij
197 schema:givenName P. P. M.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01166065522.26
199 rdf:type schema:Person
200 sg:person.01173646252.65 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
201 schema:familyName Kwekkeboom
202 schema:givenName D. J.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01173646252.65
204 rdf:type schema:Person
205 sg:person.01255444752.54 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
206 schema:familyName Krenning
207 schema:givenName E. P.
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255444752.54
209 rdf:type schema:Person
210 sg:person.015263522637.41 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
211 schema:familyName van Eijck
212 schema:givenName C. H. J.
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015263522637.41
214 rdf:type schema:Person
215 sg:person.015464766204.49 schema:affiliation https://www.grid.ac/institutes/grid.5645.2
216 schema:familyName Feelders
217 schema:givenName R. A.
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015464766204.49
219 rdf:type schema:Person
220 sg:person.0651054044.43 schema:affiliation https://www.grid.ac/institutes/grid.421513.0
221 schema:familyName Srinivasan
222 schema:givenName A.
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651054044.43
224 rdf:type schema:Person
225 sg:pub.10.1007/s002590050034 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036382831
226 https://doi.org/10.1007/s002590050034
227 rdf:type schema:CreativeWork
228 sg:pub.10.1007/s002590100490 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046278069
229 https://doi.org/10.1007/s002590100490
230 rdf:type schema:CreativeWork
231 sg:pub.10.1007/s002590100574 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045446163
232 https://doi.org/10.1007/s002590100574
233 rdf:type schema:CreativeWork
234 sg:pub.10.1111/j.1572-0241.2000.03210.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1003148742
235 https://doi.org/10.1111/j.1572-0241.2000.03210.x
236 rdf:type schema:CreativeWork
237 https://app.dimensions.ai/details/publication/pub.1074964197 schema:CreativeWork
238 https://app.dimensions.ai/details/publication/pub.1083239197 schema:CreativeWork
239 https://doi.org/10.1002/1097-0215(20010601)92:5<628::aid-ijc1244>3.0.co;2-l schema:sameAs https://app.dimensions.ai/details/publication/pub.1021202182
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1023/a:1011160913619 schema:sameAs https://app.dimensions.ai/details/publication/pub.1056305006
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1053/snuc.2002.31027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040001058
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1053/snuc/2002.31025 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031251521
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1093/jnci/85.5.365 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059818446
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1159/000201081 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043869401
250 rdf:type schema:CreativeWork
251 https://doi.org/10.3109/02841869309083916 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036734663
252 rdf:type schema:CreativeWork
253 https://www.grid.ac/institutes/grid.421513.0 schema:alternateName Mallinckrodt (United States)
254 schema:name Mallinckrodt Medical, St. Louis, Missouri USA
255 rdf:type schema:Organization
256 https://www.grid.ac/institutes/grid.5645.2 schema:alternateName Erasmus University Medical Center
257 schema:name Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
258 Department of Nuclear Medicine, Erasmus Medical Center, Dr Molewaterplein 40, 3015 GD Rotterdam, The Netherlands
259 Department of Surgery, Erasmus Medical Center, Rotterdam, The Netherlands
260 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...